Analysis Note

ControlHuman Lymphocytes

Application

This Milli-Mark Anti-CD19 -APC Antibody, clone HD37 is validated for use in FC for the detection of CD19 -APC.

Research Sub CategoryImmunoglobulins & Immunology

Research CategoryInflammation & Immunology

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

CD19 is a 120 kDa transmembrane glycoprotein with a reduced MW of 95 kDa (Pezzutto, 1987; Sato, 1997). CD19 is a member of the immunoglobulin superfamily with two extracellular C2-type domains (Pezzutto, 1987), and it is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation (Sato, 1997). CD19 expression is restricted to B cells, being absent from T cells, monocytes, and granulocytes (Pezzutto, 1987). The CD19 antigen appears early during B cell maturation, probably at late pro-B cell stage around the time of Ig heavy chain rearrangement. It then persists during all stages of B cell maturation and is lost upon terminal differentiation to plasma cells (Pezzutto, 1987).

Immunogen

Hairy cell leukemia cells

Legal Information

MILLI-MARK is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Physical form

Protein A purified

Purified Mouse monoclonal IgG1 conjugated to APC in 0.05M Tris-HCl buffer with 1% BSA, Sodium Azide at 0.097% at pH 7.2

Quality

Evaluated by flow cytometry using Human Lymphocytes

Specificity

Antibody recognizes Human CD19 antigen.

Storage and Stability

Maintained refrigerated at 2-8°C from date of receipt. Protected from light in undiluted aliquots for 6 months from date of receipt.

Target description

120 kDa (Pezzutto, 1987; Sato, 1997)